Fig. 3: Hederagenin enhanced the anticancer actions of Cisplatin. | Cell Death & Disease

Fig. 3: Hederagenin enhanced the anticancer actions of Cisplatin.

From: Hederagenin potentiated cisplatin- and paclitaxel-mediated cytotoxicity by impairing autophagy in lung cancer cells

Fig. 3

a Cisplatin-induced autophagy as indicated by increased LC3-I to -II conversion and decreased p62 level. b & c Treatment with hederagenin (50 μM) showed no or little cytotoxicity to NCI-H1299 or NCI-H1975 cells. Pre-treatment with hederagenin (50 μM) enhanced Cis-mediated inhibition at all concentrations tested (12.5, 25, and 50 μM). ***p < 0.001, ANOVA with multiple comparisons. d Co-treatment with hederagenin and Cis induced significantly higher apoptosis than Cis alone. **p < 0.01, ANOVA with multiple comparisons. e Pre-treatment with hederagenin promoted Cis-triggered Caspase-3 and PARP cleavage. Compared with a single reagent, the LC3-II level was further upregulated when the combination of hederagenin and cisplatin was administrated. f Hederagenin and cisplatin co-treatment resulted in significant increases of GFP-LC3 puncta compared with a single reagent treatment group (n = 20 cells/group). *p < 0.05, **p < 0.01,***p < 0.001, ANOVA with multiple comparisons. Scale bar, 5 μm. Cisplatin: Cis, hederagenin: Hed.

Back to article page